8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $3.2B | -$71M | 18.8% | 2.8% | -4.7% | -1.6% | $219M | $1.7B | $106M |
| 2024 | $3.3B | $90M | 20.9% | 8.1% | 5.8% | 2.0% | $236M | $2.0B | $110M |
| 2023 | $3.2B | -$679M | 19.5% | -18.7% | -46.5% | -15.1% | $143M | $2.1B | $77M |
| 2022 | $3.0B | $69M | 19.5% | 6.4% | 3.2% | 1.3% | -$18M | $2.2B | $46M |
| 2021 | $2.5B | $156M | 18.2% | 9.2% | 7.6% | 3.0% | $72M | $2.2B | $150M |
| 2020 | $1.1B | -$162M | 14.9% | 6.8% | -45.5% | -8.9% | $156M | $785M | $100M |
| 2019 | $530M | -$21M | 16.8% | 5.5% | 55.0% | -3.9% | $39M | $397M | $77M |
| 2018 | $345M | $23M | 15.0% | 9.0% | 465.2% | 6.3% | $58M | $134M | $25M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $740M | -$134M | 14.1% | -18.6% | -9.7% | -3.1% | -$21M | $1.9B | — |
| Mar '26 | $820M | -$16M | 13.6% | 0.7% | -1.1% | -0.4% | -$27M | $1.8B | $48M |
| Dec '25 | $846M | -$103M | 20.3% | -8.7% | -6.8% | -2.4% | $79M | $1.7B | $106M |
| Sep '25 | $820M | $25M | 19.7% | 7.5% | 1.5% | 0.6% | $67M | $1.8B | $80M |
| Jun '25 | $657M | $15M | 20.7% | 10.0% | 0.9% | 0.3% | $73M | $1.8B | $69M |
| Mar '25 | $778M | -$7M | 15.5% | 3.0% | -0.5% | -0.2% | -$58000 | $2.0B | $54M |
| Dec '24 | $857M | $50M | 22.4% | 11.4% | 3.2% | 1.1% | $73M | $2.0B | $110M |
| Sep '24 | $806M | $23M | 20.1% | 7.9% | 1.5% | 0.5% | $85M | $2.0B | $100M |
| Jun '24 | $806M | $19M | 21.0% | 6.5% | 1.3% | 0.4% | $117M | $2.1B | $70M |
| Mar '24 | $792M | -$2M | 19.9% | 6.4% | -0.1% | -0.0% | -$39M | $2.2B | $80M |
| Dec '23 | $858M | -$255M | 35.5% | -25.4% | -17.5% | -5.6% | $67M | $2.1B | $77M |
| Sep '23 | $804M | -$454M | 13.7% | -57.3% | -26.2% | -9.6% | $22M | $2.2B | $56M |
| Jun '23 | $793M | $14M | 15.1% | 6.8% | 0.6% | 0.3% | $4M | $2.2B | $45M |
| Mar '23 | $745M | $16M | 12.0% | 3.5% | 0.7% | 0.3% | $51M | $2.2B | $101M |
| Dec '22 | $780M | -$3M | 10.4% | 3.4% | -0.1% | -0.0% | -$46M | $2.2B | $46M |
| Sep '22 | $756M | $16M | 14.5% | 7.0% | 0.7% | 0.3% | $13M | $2.2B | $111M |
| Jun '22 | $728M | $14M | 16.2% | 8.1% | 0.7% | 0.3% | $26M | $2.2B | $119M |
| Mar '22 | $706M | $42M | 15.4% | 7.3% | 2.0% | 0.8% | -$11M | $2.2B | $119M |
| Dec '21 | $702M | $23M | 15.7% | 9.8% | 1.1% | 0.4% | $37M | $2.2B | $150M |
| Sep '21 | $653M | $58M | 18.9% | 11.6% | 2.9% | 1.1% | -$33M | $2.2B | $337M |
How the market has priced AHCO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Adapthealth Corp.'s revenue has grown 25.2% per year. These are computed facts, not advice.
As of FY2025, Adapthealth Corp. reported $1.7B of total debt against $106M of cash.
In FY2025, gross margin was 18.8%, operating margin 2.8%, and net margin -2.2%.
As of Sep '26, Adapthealth Corp. traded at a price-to-earnings ratio of about 14.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.